Toxicities Associated With PD-1/PD-L1 Blockade

Cancer J. Jan/Feb 2018;24(1):36-40. doi: 10.1097/PPO.0000000000000296.

Abstract

Immune checkpoint inhibitors, particularly those targeting PD-1/PD-L1, produce durable responses in a subset of patients across cancer types. Although often well tolerated, these agents can induce a broad spectrum of autoimmune-like complications that may affect any organ system. Treatment of these toxicities primarily consists of immune suppression with corticosteroids and other agents. This review briefly discusses the mechanisms of immune-related adverse events, overviews the clinical and pathologic features of major toxicities caused by PD-1/PD-L1 blockade, and reviews their management.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • B7-H1 Antigen / antagonists & inhibitors*
  • Humans
  • Immunotherapy / methods
  • Melanoma / immunology
  • Melanoma / metabolism
  • Melanoma / therapy*
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • B7-H1 Antigen
  • Programmed Cell Death 1 Receptor